Serine- and mannose-modified liposomal contrast agent for computed tomography: evaluation of the enhancement in rabbit liver VX-2 tumor model (pages 140–146)
Masahiro Okada, Takeshi Isoda, Seishi Kumano, Yuki Kagawa, Tetsuro Araki, Hiromitsu Onishi, Masatoshi Hori, Tonsok Kim, Yasuyuki Motokui, Takeshi Wada and Takamichi Murakami
Version of Record online: 25 MAR 2010 | DOI: 10.1002/cmmi.377
Iodinated liposomal contrast agent (ILCA) with serine and mannose modification has not been previously examined for liver enhancement. From 10 to 40 min after injection, the mean enhancement value of the liver parenchyma ROI approached 45 HU for serine-modified ILCA and 34 HU for mannose-modified ILCA. Newly developed ILCAs, such as serine-modified or mannose-modified ILCA, provide sufficient liver parenchymal enhancement at both the dynamic and delayed liver phases.